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Background Non-REM parasomnias are not uncommon conditions in the general population. 
Current treatment options are based on small case series and reports. In this study, we aimed to 
present the clinical experience from a large cohort of patients.  
Patients Five hundred and twelve patients with Non-REM parasomnia or parasomnia overlap 
disorder (POD), who had undergone a video polysomnography and were exposed to treatment, 
were retrospectively identified. Treatment outcome was assessed based on patients’ reports, and 
treatment approach on a locally accepted hierarchy of interventions.   
Results Forty percent of patients were diagnosed with sleepwalking, 23.8% with mixed-
phenotype and 10% with POD. Ultimately, 97.2% reported adequate control of their symptoms. 
Moreover, 60.1% were treated with pharmacotherapy and 32.0% without, consistent across all 
phenotypes (p=0.09). Benzodiazepines were the most common drugs prescribed (47.1%,p<0.05). 
In the end, 37.7% of our patients were receiving a benzodiazepine as part of their successful 
treatment, 11.7% an antidepressant, 9.2% a z-drug, and 10.7% melatonin. 13.2%, 12.1% and 
5.8% of our patients reported good control of their symptoms with sleep hygiene, management of 
sleep-disordered breathing, and psychological interventions (cognitive behavioral therapy (CBT) 
or mindfulness-based stress reduction (MBSR)), as monotherapy, respectively.  
Conclusion The treatment approach to effective treatment of the patients with Non-REM 
parasomnias or POD offering first sleep hygiene advice, next treatment of concurrent sleep 
disorders and management of other priming factors like stress and anxiety, and lastly 
pharmacotherapy for Non-REM parasomnia is supported by our results. Non pharmacological 
interventions were effective in one third of our patients, and CBT/MBSR and melatonin 
appeared promising new treatments.  
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Introduction 
Non rapid eye movement (NREM) parasomnias are abnormal behaviours arising primarily but 
not exclusively during non-REM stage 3 (N3) sleep. Phenotypes include sleepwalking, sleep 
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terrors, confusional arousals, sexsomnia and sleep-related eating disorder (SRED). Patients may 
also present with concurrent REM parasomnia, in a subtype of REM behaviour disorder (RBD) 
termed parasomnia overlap disorder (POD).(1-3) 
Whilst the exact mechanism underlying NREM parasomnias is unknown, a number of 
predisposing, priming and precipitating factors have been identified.(4) The mainstays of 
management of the NREM parasomnias are modulation of these factors and ensuring safety. 
Predisposing factors are thought to be primarily genetic, with many patients reporting a family 
history, and more recently genetic covariation between different phenotypes has been 
confirmed.(5-8) Thus, these factors are problematic to address. Priming factors typically increase 
the proportion and depth of N3 sleep or make arousal from it more difficult. It is postulated that 
these priming factors create a favourable environment for internal or external stimuli 
(precipitating factors) to trigger a partial arousal of the brain, manifesting as complex behaviours 
accounting for NREM parasomnia phenotypes. Potent priming factors are thought to include 
sleep deprivation, medications such as hypnotic drugs, and stress.(4) Precipitating factors include 
noise, touch from a bed partner, sleep disordered breathing (SDB) and periodic limb movements 
in sleep (PLMS).(4, 9) 
Standard management strategies include a safety plan, reassurance and general measures to 
improve sleep hygiene. Patients should be advised on avoidance of sleep deprivation, caffeine 
and alcohol consumption (especially close to bed-time), moreover, medications should be 
reviewed for known interactions.(4, 10, 11)  
Treating co-morbid sleep disorders offers an alternative strategy to improving NREM 
parasomnias. Obstructive sleep apnea (OSA), even of mild severity, or upper airway resistance 
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syndrome, can precipitate these nocturnal phenomena, and continuous positive airway pressure 
(CPAP) treatment, mandibular advancement devices or upper airway tissue reduction surgeries 
have proven to be effective especially in patients with sleep walking.(12) Restless legs syndrome 
(RLS) and PLMS have been particularly associated with SRED, and dopaminergic agents and 
alpha-2-delta ligands are considered first-line treatments.(13, 14) Insomnia can also be 
effectively treated with cognitive behavioral therapy for insomnia.(CBTi).(15, 16) 
Situational stress frequently triggers NREM parasomnias, and cognitive behavioural therapy for 
stress and anxiety (CBTs-a) can effectively alleviate this factor.(17) Mindfulness-Based Stress 
Reduction (MBSR) has been in the spotlight over the past few years, and there is evidence that it 
can improve sleep, especially when it is practiced regularly.(18, 19) Traditionally, hypnotherapy 
has been used to treat patients with NREM parasomnias, especially with sleep walking.(20) 
Anticipatory awakening before the time that NREM parasomnia events are expected to occur has 
also been utilised therapeutically.(21)  
In severe cases however, or those refractory to initial management, pharmacotherapy is valuable. 
Although presently the evidence basis for these approaches consists primarily of a limited 
number of case reports and case series, with small numbers of patients and often contradictory 
results.(14, 22) Commonly prescribed medications include benzodiazepines or benzodiazepine 
receptor agonists, and antidepressants. A major issue is that these classes of medications can 
exacerbate NREM parasomnias, worsen precipitating factors for parasomnias (such as SDB and 
PLMS), and can increase daytime somnolence.(4, 23-25) Clonazepam is commonly the first-line 
pharmacotherapy both for NREM parasomnias and RBD.(14, 22, 26-28) Antidepressants, 
including the selective serotonin reuptake inhibitors (SSRIs), tricyclics (TCAs) and the related 
drug trazodone may be of use in treating NREM parasomnias.(4, 24). Additionally, melatonin 
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can effectively re-align a delayed circadian rhythm, treat insomnia and RBD, and potentially 
improve sleep terrors and sleep walking based on a handful of case reports in children.(16, 28-
30)  
The aim of this study was to assess the effectiveness of various treatments prescribed to a large 
unselected cohort of patients with a diagnosis of NREM parasomnia with or without coexisting 
RBD. In the absence of large prospective studies, we intended to expand the evidence base of 
pharmacological and non-pharmacological interventions in these conditions.   
 
Material and Methods 
Patient selection 
Using an internal sleep laboratory database, we retrospectively identified adult patients with a 
likely diagnosis of NREM parasomnia, irrespective of other concomitant sleep disorders, 
following a consultation with an experienced sleep physician at the Sleep Disorders Centre, 
Guy's and St Thomas' Hospitals, London, UK, over a period of 7.5 years (between June 2008 and 
December 2015). Appropriate approval from the institutional review board on human research 
was obtained (project number 8126). 
All cases were retrospectively reviewed, and patients with a final diagnosis of NREM 
parasomnia or POD based on International Classification of Sleep Disorders 3rd edition (ICSD-3) 
criteria who had undergone a video polysomnography (vPSG), were included in the analysis and 
divided into six major categories (Fig. 1).(1) Patients with coexisting phenotypes of NREM 
parasomnias were grouped as mixed. None of the patients had received a prior diagnosis or 
treatment for NREM parasomnia, POD or other sleep disorders, except from patients with 
insomnia diagnosed in primary care and exposed to hypnotic agents, in order to explore the 
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significance of the latter as priming factors for NREM parasomnia. Patients without follow up 
(FU) or lost to FU were excluded from the analysis. Demographics, medical history and 
medications of the cohort were derived from medical records. A standardised diagnostic 
approach was shared between clinicians with the intention to order vPSG for all patients.    
Treatment 
All patients received general safety recommendations and sleep hygiene advice prior to initiation 
of any other treatment. A sleep hygiene leaflet which included but was not limited to measures 
on or around bedtime habits, keeping a regular sleep/wake pattern and adequate sleep 
opportunity was offered to all the patients. Sleep hygiene effectiveness was assessed as an 
overall outcome and individual measures were not assessed separately. Further treatment was 
guided by clinically or polysomnographically identified concurrent sleep disorders and attention 
was paid on managing stress and anxiety with or without pharmacotherapy. Patients who had 
been refractory to any intervention up to this point, or without obvious priming and precipitating 
factors, were initiated on or trialed on different classes of medications, without a formal 
consensus on the sequence or the type of drug used. MBSR and melatonin were only utilised for 
the last two years of the study period. Treatment success was based on patients' subjective 
reports of either total resolution or satisfactory control of their parasomnia symptoms, and 
without experiencing drug-related side effects that would have limited their usage. Medical 
records were searched for priming factors associated with NREM parasomnia, without a pre-
established list, including sleep deprivation, stress, insomnia, hyperthyroidism, migraines, 
history of head injury, encephalitis and stroke, and drugs including lithium, phenothiazines, 
anticholinergic agents and hypnotic drugs. Sleep deprivation was captured through sleep diaries 
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or/and home actigraphy (7-/14-days), and stress was self-reported. The diagnosis of insomnia 
was made based on the existing ICSD criteria at the time of the diagnosis.  
The following precipitating factors, including external stimuli such as noise, light and bed 
partner's movements, and internal stimuli including SDB and PLMS, were extracted from 
patients' records without a pre-established list, and vPSG respectively.  
   
Sleep Study Methodology  
Attended inpatient vPSG was performed using standard 10–20 EEG montage, with sleep stages 
scored according to the standard criteria of the American Academy of Sleep Medicine (AASM). 
Continuous recordings included electrooculography, electrocardiography, submental and leg 
electromyography, pulse oximetry, nasal pressure cannulae, and respiratory inductance 
plethysmography, with chest and abdominal belts.(31) Time-synchronized video recordings were 
also performed, while audio was captured by a multidirectional microphone placed above the 
patient. In patients requiring multiple sleep latency testing for diagnostic purposes of 
concomitant sleep disorders, standard guidelines were applied.(32)  
Apneas and hypopneas, periodic limb movements in sleep (PLMS), and REM without atonia 
(RWA), were scored following standard AASM definitions to determine the apnea–hypopnea 
index (AHI) and PLM-index (PLMI), using as cut-offs the 5 events/h and 15 events/h for the 
diagnosis of obstructive sleep apnea (OSA) and PLMS respectively.(31)  
All cases of concomitant diagnosis of hypersomnia of central origin were retrospectively 
reviewed and diagnosis was made de novo according to ICSD-3 criteria.(1) These patients had 
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presented at the time of first consultation both with NREM parasomnia and hypersomnia of 
central origin features and they were treatment naive.   
 
Statistical analysis 
 
Data are reported as mean ± standard deviation (SD) if not otherwise indicated. Following 
testing for normality, comparisons between the six groups were performed using the Kruskal–
Wallis test, with Dunn’s Multiple Comparison Test when needed. A Chi Square test was used for 
correlations between variables. A value of p < 0.05 was considered to be statistically significant. 
IBM SPSS Statistics V24.0 (SPSS, Chicago, IL/USA) was used for all statistical analysis. 
 
Results 
Based on clinical history, 627 patients with a possible diagnosis of NREM parasomnia were 
identified. Five hundred and twelve patients (265 males, (51.8%)) with age ranging from 19 to 
88 years old and with a mean of 39.3±12.1 years,  had undergone a vPSG and had their diagnosis 
secured, and were exposed to treatment with adequate follow up time of at least six months 
(median 8.0 months (interquartile range 7.0-11.0) of follow up time (FU)). (Fig. 1) 40.0% 
(206/512) were diagnosed with sleepwalking alone, and 23.8% (122/512) had a mixed 
phenotype. (Fig 1) POD patients were the oldest among the groups (p=0.023). A clear male 
predominance was observed in the sexsomnia group (87.7%, p=0.017). (Table 1) 22.0% 
(113/512) were diagnosed with OSA (AHI: 18.6±15.5 events/h) and 11.1% (57/512) with PLMS 
(PLMI: 33.2±23.6 events/h), and there was no difference between studied groups (p>0.05, Table 
1); patients in the SRED cohort did not have a higher prevalence of PLMS.  
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Table 1. Demographics and concomitant sleep disorders of the studied groups. 
  
Diagnosis 
 
Demographics 
 Sleepwalking 
n=206 
Sleep 
terrors 
n=72 
Confusional 
arousals, 
n=39 
Sexsomnia 
n=15 
SRED 
n=7 
Mixed 
n=122 
POD 
n=51 
P value 
Age (y)  38.5±11.3 38.9±14.3 42.9±14.3 36.9±8.0 43.8±18.2 37.2±10.6 45.1±14.9 0.023* 
Gender (m, %)  52.4 40.3 53.8 86.7 28.6 49.2 62.7 0.017# 
BMI (Kg/m2)  27.3±5.1 25.7±4.6 29.1±7.2 25.9±5.0 26.2±5.3 27.4±4.7 27.2±4.0 0.203 
ESS  9.6±5.8 9.1±4.4 11.5±6.6 9.9±6.5 8.5±6.0 8.7±5.2 10.5±4.8 0.201 
 
         
Concomitant sleep disorders 
OSA, n (%)  45 (21.8) 12 (16.7) 13 (33.3) 7 (46.7) 2 (28.6) 21 (17.2) 13 (25.5) 0.072 
PLMS, n (%)  20 (9.7) 4 (5.6) 6 (15.4) 4 (26.7) 1 (14.3) 12 (9.8) 10 (19.6) 0.087 
NT1/NT2/IH, n  1/1/5 0/0/1 0/2/1 0 (0) 0 (0) 0 (0) 0 (0) 0.063 
 
SRED, sleep related eating disorder; Mixed, mixed phenotypes of NREM parasomnia; NREM, non-REM; POD, 
parasomnia overlap disorder; ESS, Epworth sleepiness scale; OSA, obstructive sleep apnea; PLMS, periodic limb 
movements during sleep; NT1, narcolepsy type 1; NT2, narcolepsy type 2; IH, idiopathic hypersomnia; y, years; m, 
male; n, number.  
* Mixed versus POD (p=0.027) using Independent Samples Kruskal-Wallis Test with Dunn’s Multiple Comparison 
Test 
# Chi Square with Cramer's V product. 
 
 
Furthermore, 97.2% (498/512) of the patients reported that their parasomnia manifestations were 
at least under an acceptable level of control for them individually or they have totally resolved; 
and 32.0% (164/512) did not require pharmacotherapy, using either sleep hygiene, CPAP/MAD, 
CBT/MBSR, acupuncture or by discontinuing drugs deemed responsible for triggering NREM 
parasomnia. Pharmacotherapy alone, as monotherapy or combination of drugs, targeting the 
NREM parasomnia or concomitant sleep disorders like PLMS, treated the 60.1% of the cohort, 
and that was independent of the diagnosis (p=0.09). (Table 2)  
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The type of successful treatment differed between phenotypes (p<0.0001, Table 2). The majority 
of the patients for all groups except SRED, were treated with pharmacotherapy alone, after sleep 
hygiene advice. Notably, 48.7% of the patients with confusional arousals were treated with 
CPAP/MAD or sleep hygiene advice alone, while three out seven patients with SRED required 
combination of treatments and one out of seven reported successful control of the symptoms 
after attending a course for cognitive behavioral treatment for insomnia. (Table 2) 
 
 
 
 
 
 
 
 
 
 
Table 2.  Type of successful treatment used per diagnosis.  
  Diagnosis   
Treatment options  
 
Sleepwalking 
 
Sleep 
terrors 
n, (%) 
Confusional 
arousals, 
n, (%) 
Sexomnia 
 
n, (%) 
SRED 
 
n, (%) 
Mixed 
 
n, (%) 
POD 
 
n, (%) 
Total 
 
n, (%) 
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n, (%) 
Pharmacotherapy# 
 
 
122  
(59.2) 
 
42  
(58.3) 
 
16  
(41.0) 
 
9  
(60.0) 
 
2  
(28.6) 
 
82  
(67.2) 
 
35  
(68.6) 
 
308 
 (60.1) 
 
Sleep hygiene 
advice 
 
 
37  
(17.9) 
 
11  
(15.2) 
 
10  
(25.6) 
 
0 
 
0 
 
8  
(6.5) 
 
2  
(3.9) 
 
68  
(13.2) 
 
CPAP/MAD 
 
 
22 
 (10.6) 
 
6 
 (8.3) 
 
9 
 (23.1) 
 
3  
(20.0) 
 
1  
(14.3) 
 
13  
(10.6) 
 
8  
(15.6) 
 
62  
(12.1) 
 
CBTi/CBTs-
a/MBSR 
 
 
12  
(5.8) 
 
6  
(8.3) 
 
2  
(5.1) 
 
1  
(6.6) 
 
1  
(14.3) 
 
8  
(6.5) 
 
0 
 
30 
 (5.8) 
 
Combination of 
treatments* 
 
 
 
10  
(4.8) 
 
 2  
(2.8) 
 
 2  
(5.1) 
 
0 
 
3  
(42.9) 
 
7  
(5.7) 
 
2  
(3.9) 
 
26  
(5.0) 
Discontinuation of 
medication 
 
1 
(0.5) 
1 
(1.4) 
0 0 0 0 1 
(1.9) 
3 
(0.6) 
 
Acupuncture 
 
 
0 
 
1 
(1.4) 
 
0 
 
0 
 
0 
 
0 
 
0 
 
1  
(0.2) 
Failed treatment  
 
 
2 (0.9) 
 
 
3 (4.1) 
 
 
0 
 
 
2 (13.3) 
 
 
0 
 
 
4 (3.2) 
 
 
3 (5.8) 
 
 
14 (2.7) 
 
Total 206 (100) 
72 
(100) 
39 
(100) 
15 
(100) 
7 
(100) 
122 
(100) 
51 
(100) 
512 
(100) 
 
SRED, sleep related eating disorder; Mixed, mixed phenotypes of NREM parasomnia; NREM, non-REM; POD, 
parasomnia overlap disorder; CPAP, continuous positive airway pressure; MAD, mandibular advancement device; 
CBTi, cognitive behavioral treatment for insomnia; CBTs-a, cognitive behavioral treatment for stress and anxiety; 
MBSR, mindfulness-based stress reduction program; #, monotherapy or combination of drugs; *, combination of 
pharmacological treatment and not on top of sleep hygiene advice. 
 
 
 
 
 
Sleep hygiene 
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Moreover, 13.2% of our patients, primarily those with confusional arousals, sleepwalking and 
sleep terrors, (p=0.003) had to implement only sleep hygiene in their daily life in order to 
achieve satisfactory control of their symptomatology. (Table 2, Table 3 and Figure 2)  
 
Pharmacotherapy 
 
Four hundred and forty-six out of 512 patients required further intervention following the 
implementation of sleep hygiene, and pharmacotherapy was utilized next in 350 of them 
(78.4%). Benzodiazepines were first drugs most commonly used (173/350, (49.4%)) with the 
best success rate at 72.2% (p<0.001) compared to z-drugs, antidepressants and melatonin 
(49.1%, 37% and 38.2% respectively). (Fig. 2) Overall, almost half of our patients were exposed 
to benzodiazepines, primarily clonazepam, and 80% had a good response irrespective of the 
diagnosis (p=0.933). In addition, 37.7% of our patients received a benzodiazepine as part of their 
successful treatment combination (Table 3), and 29.7% (152/512) of the patients were treated 
with benzodiazepine alone. (Figure 2)  
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Table 3.  Therapeutic options and outcome. 
  
   Treatment outcome and information 
Pharmacotherapy  
 
Exposed  
 
n, (%) 
Success  
rate 
n, (%) 
P value* 
per diagnosis 
 
As a standalone 
treatment 
n, (%) 
Treated  
with  
n, (%) 
Commonest  
drug/treatment 
(%) 
Dose 
 
mg±SD 
 
Benzodiazepines 
  
241/512 
(47.1) 
 
193/241 
(80) 
 
0.933 
 
 
152/193  
(78.8) 
 
193/512   
(37.7) 
 
Clonazepam 
(95.8) 
 
0.63±0.64 
 
Z-drugs 
  
81/512 
(15.8) 
 
47/81 
(58) 
 
0.728 
 
 
35/47     
(74.5) 
 
47/512       
(9.2) 
 
Zopiclone 
(100) 
 
4.14±1.16 
 
Antidepressants 
 
  
97/512  
(18.9) 
 
60/97 
(61.8) 
 
0.551 
 
36/60     
(60.0) 
 
60/512       
(11.7) 
 
Fluoxetine 
(31.6) 
 
13.3±4.9 
 
Melatonin, PR 
  
71/512  
(13.9) 
 
55/71 
(77.4) 
 
0.066 
 
 
28/55     
(50.9) 
 
55/512      
(10.7) 
 
N/A 
 
2.4±1.0 
 
Dopamine agonist 
  
10/512      
(1.9) 
 
8/10 
(80) 
 
0.040 
 
 
8/8         
 (100) 
 
8/512         
(1.5) 
 
Ropinirole 
(62.5) 
 
1.4±0.5 
 
Pregabalin/ 
Gabapentin# 
  
5/512      
(0.9) 
 
4/5  
(80) 
 
0.659 
 
 
4/4 
(100) 
 
4/512         
(0.7) 
 
Pregabalin 
(50) 
 
300±0 
 
        
 
CPAP/MAD  92/512 
(17.9) 
79/92 
(85.8) 
0.105 62/79       
(78.4) 
79/512     
(15.4) 
CPAP     
(72.5) 
N/A 
 
        
CBTi/CBTs-
a/MBSR 
 40/512  
(7.8) 
32/40 
(0.8) 
0.412 
 
30/32       
(0.93) 
30/512  
(5.8) 
CBTi       
(42.5) 
N/A 
 
       
Sleep hygiene 
advice 
 512/512 
(100) 
N/A <0.001 
 
68/512     
(13.2) 
N/A N/A N/A 
 
SD, standard deviation; n, number; SSRIs, serotonin selective reuptake inhibitors; SARI, serotonin antagonist and 
reuptake inhibitor; TCAs, tricyclic antidepressants; PR, prolonged-release; CPAP, continuous positive airway 
pressure treatment; MAD, mandibular advancement device; CBTi, cognitive behavioural treatment for insomnia; 
CBTs-a, cognitive behavioural treatment for stress and anxiety; MBSR, Mindfulness-based stress reduction 
program; N/A, not applicable; #, these medications were prescribed for restless leg syndrome /periodic limb 
movement disorder. 
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*: P value reflects on success rate comparison between different diagnoses and was calculated using Chi Square test 
with Cramer's V product and Fischer's exact test as required. 
 
 
Zopiclone, was constituted as a successful treatment either in part or in whole for 9.2% of the 
patients irrespective of their diagnosis (p=0.728). Of the 15.8% who were exposed to the drug 
two thirds of them responded well, with the majority receiving it as monotherapy. (Table 3) 
Following sleep hygiene advice, 12.7% of patients received zopiclone and half of them (49.1%) 
had their symptoms successfully controlled. (Fig. 2)    
Antidepressants were prescribed in 18.9% of our patients and 11.7% were receiving an 
antidepressant as part of their successful treatment, irrespective of their diagnosis (p=0.551). 
Fluoxetine was the most common antidepressant prescribed (31.7% (19/60), Table 3) followed 
by citalopram (20.0%), mirtazapine and trimipramine (8.3%, respectively), amitriptyline (6.7%), 
paroxetine, sertraline, clomipramine and trazodone (5.0%, respectively), imipramine (3.3%) and 
venlafaxine (1.6%). Twelve point one percent of our patients received an antidepressant as their 
first intervention following sleep hygiene advice and a third of them (37%) responded well. (Fig. 
2) 
Fifty- five out of 512 patients (10.7%) were treated with melatonin which was provided in a 
sustained release preparation. The majority consisted of patients with POD (32.7%), 
sleepwalking (29.1%), and mixed phenotype (21.8%), (p<0.001, Table 4). Half of the patients 
that were successfully treated with melatonin, were receiving it as monotherapy (Table 3), and 
these were primarily patients with POD, sleepwalking and mixed phenotype (p<0.001, Table 4). 
Similar to antidepressants and z-drugs, a 12.1% of our patients that failed sleep hygiene were 
prescribed melatonin and 38.2% reported good control of their symptoms. (Fig. 2)  
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Table 4. Patients successfully treated with melatonin. 
  
 
Diagnosis 
 
 
Melatonin MR 
 
 
Sleepwalking 
 
n, (%) 
Sleep 
terrors 
n, (%) 
Confusional 
arousals 
n, (%) 
Sexsomnia 
 
n, (%) 
SRED 
 
n, (%) 
Mixed 
 
n, (%) 
POD 
 
n, (%) 
 
P value 
 
Treated with 
(n=55) 
 
16 (29.1) 3(5.4) 4 (7.3) 0 2 (3.6) 12 (21.8) 18 (32.7) <0.001 
As a standalone 
treatment 
(n=28) 
 
6  (21.4) 2 (7.2) 4 (14.3) 0 0 6 (21.4) 10 (35.7) <0.001 
 
MR: modified release; SRED, sleep related eating disorder; Mixed, mixed phenotypes of NREM parasomnia; POD, 
parasomnia overlap disorder. 
*: P value was calculated using Chi Square with Fischer's exact test.  
 
 
11.1% (57/512) of the patients were diagnosed with PLMS, and 26.3% of them (15/57) received 
treatment targeting PLMS (8 received dopamine agonist, 4 pregabalin, 2 had iron 
supplementation and 1 had SSRI-related PLMS which resolved after discontinuation of the drug) 
with subsequent good control of the nocturnal abnormal manifestations. (Table 3 and Figure 2) 
Another 29.8% (17/57) were treated with benzodiazepine alone, and 15.8% (9/57) with 
zopiclone or a combination of sedative drugs. In 17.5% of the patients with PLMS, CPAP/MAD 
treatment was applied for concomitant OSA offering good control of the parasomnia symptoms, 
and in 3 more cases benzodiazepine had to be added on top of CPAP/MAD. 1 patient with PLMS 
did not receive any treatment except from sleep hygiene advice and general recommendations, 
while 2 patients failed treatment with benzodiazepine and zopiclone. PLMI did not differ 
significantly between those received PLMS-targeted treatment and those that did not (p=0.508). 
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We identified three cases of drug-related NREM parasomnias; one with SSRI induced PLMS 
and another two with sleepwalking, and sleep terrors receiving zaleplon for insomnia.  In all 
three cases the NREM parasomnia resolved after the discontinuation of the drugs.  
 
CPAP/MAD 
One hundred and thirteen out of 512 (22.0%) of  patients were diagnosed with OSA and 81.4% 
of those received either CPAP if at least moderate OSA was confirmed, or a custom made MAD 
for milder conditions. The rest of the patients declined or could not tolerate any of the two 
treatments (n=21) and had a significantly lower AHI (21.6±16.3 vs 8.3±2.2 events/h, p<0.001). 
Of those, 85.7% of patients receiving any of the two treatments had satisfactory control both of 
OSA and their parasomnia events. Moreover, in 78.4% of these cases no other treatment was 
required (CPAP, n=45; MAD, n=17). The success rate was similar between studied groups 
(p=0.105). AHI and compliance did not differ significantly between those reporting good 
response to CPAP/MAD and those that did not (p=0.669 and p=0.178). (Table 3) 75% of the 
patients that were exposed to CPAP/MAD had this treatment applied as first intervention 
following sleep hygiene advice, and the majority (81.1%) of them required no further treatment. 
(Fig. 2)  
 
CBTi, CBTs-a, MBSR 
Forty patients were referred to attend a CBT or MBSR, with a success rate of 80% (32/40) which 
did not differ between groups (p=0.412). Of those that were successfully treated, 13 had CBTi, 
10 CBTs-a, and 7 MBSR not requiring any additional treatment. The selection of the patients 
was based on clinician’s preference when increased levels of stress and anxiety were identified, 
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or when insomnia was diagnosed and the sleep study had excluded other concomitant sleep 
disorders. 25 out of 40 that had a CBT or MBSR, attended the course following sleep hygiene 
advice and prior to any other treatment, and all but one patient reported successful control of 
their symptoms. (Fig. 2)  
  
 
 
Discussion 
 
 This study reports the largest cohort of patients diagnosed and treated for NREM parasomnias 
currently described in the literature, covering the full spectrum of the condition, including those 
with POD. The treatment approach started with sleep hygiene advice and a safety plan, followed 
by treatment of concurrent sleep disorders and of other priming and precipitating factors, and 
when required by NREM parasomnia or POD-targeted pharmacotherapy, yielding a 97.2% 
subjective satisfaction of symptom control for our patients. Pharmacotherapy alone, as 
monotherapy or a combination of drugs, remained a pivotal component of successful treatment 
for our patients (60.1%), but it should be highlighted that one third of the patients did not require 
any pharmacotherapy. This study strengthens the existing data on effectiveness of different types 
of drugs and interventions, and also introduces melatonin as a treatment of NREM parasomnia in 
adults, and CBT/MBSR in selected cases with promising results.  The type of successful 
treatment differed with diagnosis (p<0.0001) giving rise to more tailored and phenotype-guided 
treatment options in future clinical practice. 
Reassurance, safety measures and sleep hygiene advice should be the first line of treatment for 
patients with NREM parasomnia. 12.9% of our cohort did not require any further interventions, 
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and ultimately 25.6% of the patients with confusional arousals, 17.9% with sleepwalking and 
15.2% with sleep terrors, were treated successfully using this approach. Reassurance should 
include explaining to patients that the nocturnal manifestations of NREM parasomnia are not 
part of a psychopathology, while plans to avoid injuries are also discussed, like locked windows 
and bedroom doors or use of bedroom door alarms, removal of bedside objects that could cause 
injuries, and advice to avoid forced awakening of the patient during a NREM parasomnia 
event.(14) Sleep deprivation is a common trigger of NREM parasomnias; sleep hygiene leaflets 
are easily accessible over the internet and should ideally be offered at the stage of primary care 
assessment. In cases where NREM parasomnia overlaps with RBD or RWA, information should 
be offered that the latter two can often predate the development of Parkinson’s disease and other 
disorders of synuclein pathology. Assessment of these patients for early signs of these conditions 
like constipation and olfactory deficiencies is recommended.(33, 34) 
31.2% (160/512) of the patients were diagnosed with at least one concomitant sleep pathology 
(OSA, PLMS and hypersomnia of central origin) following vPSG and MSLT when required. 
17.8% (91/512) received treatment targeting their concurrent sleep pathologies, and reported 
satisfactory control of the abnormal nocturnal manifestations, irrespective of their NREM-
parasomnia phenotype and the severity of OSA or PLMS; our findings are in line with existing 
reports. Moreover, this is the first time that treatment of OSA and PLMS in NREM parasomnias 
is supported on a large scale, irrespective of the NREM-parasomnia phenotype.(12-14) These 
results would support the recommendation included in the ICSD3 of performing vPSG in 
complicated NREM parasomnia cases where another sleep diagnosis, like OSA and PLMS may 
coexist.(1)  
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Hypnotherapy aims to induce physical relaxation, and based on current literature has been 
utilised successfully in managing a few patients with NREM parasomnias and rarely with 
POD.(35, 36) CBTs-a and CBTi are based on psychosocial interventions and they focus on 
reducing stress and anxiety levels, and resolve insomnia, respectively, which are all well-known 
precipitating factors for NREM parasomnias. Along the same lines, MBSR which helps 
individuals self-manage and reframe worrisome and intrusive thoughts, aims at stress reduction 
and has been a promising treatment for insomnia.(18, 19) Since hypnotherapy was not easily 
accessible to our patients, 40 patients without OSA, PLMS or central hypersomnia, and with the 
aforementioned priming factors present, were selected to attend a type of CBT or MBSR as felt 
to be clinically appropriate. Thirty two responded well and 30 did not require any additional 
treatment. Among them there were two pregnant women, and these non-pharmaceutical 
interventions would be an ideal option for this sub-group of patients. While we acknowledge the 
selection bias and the limitation of the study design to compare treatments, our results provide 
enough clinical support that these interventions could be viable treatment options and further 
studies will be required to give credence to that.  
 In line with existing data, clonazepam was the drug most commonly used (37.7%, p<0.001), and 
pharmacotherapy alone was the primary source of successful treatment for our patients 
(60.1%).(26, 37) The success rate of clonazepam (72.2%) whenever used as a first line drug, and 
compared to the rest of the drugs (p<0.001), would support our clinical experience that this 
should be a first line option especially when patients or bed-partners have sustained or are likely 
to sustain injuries, and after other sleep pathologies have been excluded or treated, and risk of 
fall or drug abuse has been taken into consideration.(26, 38)  
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Hypnotic drugs, especially zolpidem and zaleplon, have been linked to SRED and other NREM 
parasomnias.(4, 11) Notably, zopiclone was offered to 81 of our patients and 47 (9.2% of the 
cohort) were successfully treated, with the addition of other treatments when needed. None of the 
patients that failed to respond to zopiclone reported any noticeable increase in the frequency of 
nocturnal events. Therefore, zopiclone could be considered a treatment option for these patients, 
especially when patients require pharmacotherapy and suffer from concomitant insomnia too. Α 
difference in pharmacodynamics between z-drugs could offer a possible explanation for the 
discrepancies mentioned above. This hypothesis could be based on the recently described 
paradoxical effect of zolpidem in patients with OSA where muscle activity was increased during 
airway narrowing compared to zopiclone and placebo, while the arousal threshold was increased 
similarly for both of the z-drugs.(39)  
Eleven antidepressants, including SSRIs and TCAs, were used as part of the successful treatment 
of 11.7% of our patients. The most commonly used were fluoxetine, citalopram and 
mirtazapine.(14, 22) None of the pharmaceutical categories above (benzodiazepines, z-drugs, 
antidepressants) showed different effectiveness per diagnosis (p>0.05, Table 3).   
Prior to introducing melatonin to our patients with NREM parasomnia, we observed cases of 
POD where patients receiving this drug were reporting adequate control both of RBD and 
NREM parasomnia events. In this study, 10.7% of our cohort were treated successfully with 
melatonin (Table 3, Figure 2). The majority of these patients were suffering from POD (32.7%, 
p<0.001), but notably there were another 29.1% suffering from sleepwalking and 21.8% with 
mixed phenotype. (Table 4) We hypothesize that sleep consolidation, treatment of sleep 
deprivation (4/55 of patients treated with melatonin) or of concomitant insomnia (3/55), are 
potential effects by which melatonin is managing to control NREM parasomnia.(30, 40)  
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Considering the good safety profile and these promising results, especially when compared to z-
drugs or antidepressants, melatonin is proposed as one of the first line pharmacotherapy options 
in patients with NREM parasomnias or POD, however, future studies will be required to support 
this statement. 
In summary, these data provide supportive evidence for standard therapies proposed for NREM 
parasomnias, but also lend support for the use of melatonin, zopiclone and psychological 
therapies such as CBT and MBSR. Furthermore, these data also support the tackling of sleep 
comorbidities such as SDB and RLS/PLMS before utilizing specific pharmacotherapies directed 
at NREM parasomnias. 
Limitations 
It should be noted that there are several limitations to our study. First, the study design was 
retrospective and treatment success was based on patients' reports and their ability to recollect 
past events considering the retrograde amnesia usually associated with NREM parasomnia, 
which may explain the observed high success rate. Nonetheless, the essence of the treatment aim 
in patients with parasomnias in clinical practice is safety and addressing patients' symptoms 
adequately as per their criteria. Validated questionnaires on parasomnia severity, such as the 
Munich Parasomnia Screening (MUPS) questionnaire, would be recommended for future 
prospective studies adding objective data to our results.(41) The utilization of a standardised list 
of predisposing, priming and precipitating factors would also be helpful in future studies.  
In the context of a retrospective study, while CPAP compliance was confirmed, CBT and MBSR 
attendances and medication compliance were not, and this may have had an impact on our 
results. We also acknowledge that patients that received CBT or MBSR were subject to selection 
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bias, and so these results should not be generalised, although blanket psychological therapies for 
NREM parasomnias could be the focus of future studies. Finally, this study provides information 
on drugs' effectiveness based on clinical practice and not on direct comparison between different 
treatment elements.     
Conclusion 
Based on a high success rate our findings would support a standardised treatment approach for 
patients with NREM parasomnia or POD. Treatment of concomitant sleep disorders and more 
importantly of OSA even in mild forms should be a priority. Clonazepam was the most 
commonly used and effective drug irrespective of diagnosis, and antidepressants and zopiclone 
remain viable options. Results from melatonin administration were promising and its safety 
profile may promote this medication as first line pharmacotherapy option in the future. CBT and 
MBSR can be considered prior to or as an alternative to pharmacotherapy in selected patients.  
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Figure 1. Flow diagram of the studied cohort. 
Percentages indicate the prevalence of each diagnostic group in our cohort of 512 patients. NREM, non-REM; POD, 
parasomnia overlap disorder; vPSG, video polysomnography; SRED, sleep related eating disorder; Mixed, mixed 
phenotypes of NREM parasomnia; n, number.  
 
 
Figure 2. Treatment approach and outcome for 512 patients with NREM parasomnia or POD.  
NREM, non-REM; POD, parasomnia overlap disorder; CPAP, continuous positive airway pressure; MAD, 
mandibular advancement device; CBT,  cognitive behavioral treatment; MBSR, mindfulness-based stress reduction 
program; DA, dopamine agonist; Anticonvulsant, pregabalin or gabapentin; Stimulant, modafinil; Combination of 
treatments, combination of more than one treatment options. 
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• This study supports a standardised treatment approach in NREM-parasomnias. 
• Pharmacotherapy alone effectively treated two third of the patients.  
• One third of the patients were effectively treated without pharmacotherapy.   
• Treatment of sleep apnea and periodic limb movements in sleep is recommended.    
• Melatonin and psychological therapies are promising treatment options.  
